Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil

Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil

This prospective, observational, open-label study aimed to provide access to ustekinumab prior to market authorization and assess its safety and effectiveness in patients with Crohn’s disease (CD) refractory to anti-tumor necrosis factor-α and conventional drugs in Brazil. Patients with a diagnosis...

Full description

Bibliographic Details
Main Authors: Julio Maria Fonseca Chebli, Rogério Serafim Parra, Cristina Flores, Antonio Carlos Moraes, Rodrigo Bremer Nones, Tarcia Nogueira Ferreira Gomes, Ana Maria Bravo Perdomo, Gustavo Scapini, Cyrla Zaltman
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Journal of Clinical Medicine
Subjects:
biological products
ustekinumab
crohn’s disease
early access program
Online Access:https://www.mdpi.com/2077-0383/11/21/6481

Internet

https://www.mdpi.com/2077-0383/11/21/6481

Similar Items